文献速递淋巴瘤

晚期结外NK/T细胞淋巴瘤预后改善:NKEA-Next研究结果

Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study.
PubMed 文献 · Leukemia · 2025-02-17

日本2014至2021年诊断的351例结外NK/T细胞淋巴瘤患者中,116例(33%)为晚期(III期5例、IV期111例)并进一步分析。中位年龄60岁,男性68例(59%),94例(85%)IV期患者有≥2处结外受累。最常见一线方案为SMILE(52%)。全组2年OS 38.5%,2018-2021年较2014-2017年显著改善(50.7% vs 25.2%,P=0.008)。SMILE组2年OS优于DeVIC组和CHOP组(57.1% vs 35.8% vs 0%,P<0.001)。接受HSCT者2年OS优于未接受者(68.3% vs 17.6%,P<0.001)。多因素分析显示SMILE和HSCT为OS的显著因素。

要点

  • 晚期ENKL全组2年OS为38.5%,2018-2021年较2014-2017年显著改善(50.7% vs 25.2%,P=0.008)。
  • SMILE组2年OS优于DeVIC组和CHOP组(57.1% vs 35.8% vs 0%,P<0.001)。
  • 接受HSCT者2年OS优于未接受者(68.3% vs 17.6%,P<0.001)。

核心结论

  • 晚期结外NK/T细胞淋巴瘤的预后近年来有所改善。
  • 含L-天冬酰胺酶的化疗及后续HSCT被认为是推荐策略。

研究设计与样本

  • 日本2014至2021年诊断的结外NK/T细胞淋巴瘤患者的回顾性研究。
  • 351例数据充分患者中116例(33%)诊断时为晚期(III期5例、IV期111例)并进一步分析。
  • 中位年龄60岁(范围19-90岁),男性68例(59%)。
  • 94例(85%)IV期患者有≥2处结外受累。

主要发现

  • 最常见一线方案为SMILE(52%)。
  • 全组2年OS为38.5%。
  • 2年OS在2017年后显著改善:2014-2017年为25.2%,2018-2021年为50.7%(P=0.008)。
  • SMILE组、DeVIC组和CHOP组的2年OS分别为57.1%、35.8%和0%(P<0.001)。
  • 接受HSCT者与未接受者的2年OS分别为68.3%和17.6%(P<0.001)。

临床怎么用

  • 作者认为含L-天冬酰胺酶的化疗及后续HSCT是晚期ENKL的推荐策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A retrospective study of extranodal natural killer/T-cell lymphoma (ENKL) patients diagnosed between 2014 and 2021 in Japan was conducted. Among 351 patients with sufficient data, 116 (33%) were in the advanced stage (5 in stage III and 111 in stage IV) at diagnosis, and were further analyzed. The median age was 60 years (range: 19-90), and 68 (59%) were male. Ninety-four (85%) of stage IV patients had two or more extranodal involvements. The most common first-line regimen was SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide; 52%). The 2-year overall survival (OS) for all patients was 38.5%, which was significantly improved after 2017 (25.2% for 2014-2017 vs. 50.7% for 2018-2021; P = 0.008). Patients treated with SMILE showed better OS than those treated with DeVIC or CHOP (2y-OS: 57.1%, 35.8%, and 0%, respectively; P < 0.001). The prognosis was significantly better in patients who received hematopoietic stem cell transplantation (HSCT) than in those who did not (2-year OS: 68.3% vs. 17.6%, P < 0.001). Multivariate analysis showed SMILE and HSCT were significant factors for OS. In conclusion, the prognosis of advanced-stage ENKL has improved in recent years. The L-asparaginase-containing chemotherapy and subsequent HSCT is considered the recommended strategy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Fujimoto A, Miyazaki K, Yakushijin K, et al. Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study. Leukemia. 2025. PMID: 39962328. doi:10.1038/s41375-025-02527-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。